SG11201601145RA - Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough - Google Patents
Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic coughInfo
- Publication number
- SG11201601145RA SG11201601145RA SG11201601145RA SG11201601145RA SG11201601145RA SG 11201601145R A SG11201601145R A SG 11201601145RA SG 11201601145R A SG11201601145R A SG 11201601145RA SG 11201601145R A SG11201601145R A SG 11201601145RA SG 11201601145R A SG11201601145R A SG 11201601145RA
- Authority
- SG
- Singapore
- Prior art keywords
- acute
- diaminopyrimidine
- sub
- treatment
- receptor modulators
- Prior art date
Links
- 206010011224 Cough Diseases 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 208000013116 chronic cough Diseases 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869174P | 2013-08-23 | 2013-08-23 | |
| PCT/US2014/052389 WO2015027212A1 (en) | 2013-08-23 | 2014-08-22 | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601145RA true SG11201601145RA (en) | 2016-03-30 |
Family
ID=52480919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601145RA SG11201601145RA (en) | 2013-08-23 | 2014-08-22 | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9284279B2 (enExample) |
| EP (2) | EP3865134A1 (enExample) |
| JP (3) | JP6546592B2 (enExample) |
| KR (1) | KR102196885B1 (enExample) |
| CN (1) | CN105682659B (enExample) |
| AU (1) | AU2014308606B2 (enExample) |
| CA (1) | CA2921395C (enExample) |
| CL (3) | CL2016000400A1 (enExample) |
| CR (1) | CR20160093A (enExample) |
| IL (1) | IL244131B (enExample) |
| MX (1) | MX367657B (enExample) |
| MY (1) | MY195728A (enExample) |
| NI (1) | NI201600029A (enExample) |
| NZ (1) | NZ716977A (enExample) |
| PE (1) | PE20160431A1 (enExample) |
| PH (1) | PH12016500357A1 (enExample) |
| RU (1) | RU2650118C2 (enExample) |
| SG (1) | SG11201601145RA (enExample) |
| UA (1) | UA118851C2 (enExample) |
| WO (1) | WO2015027212A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX367657B (es) | 2013-08-23 | 2019-08-30 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
| CA2938996A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the treatment of lung diseases with mast cell stabilizers |
| US9962363B2 (en) | 2014-02-10 | 2018-05-08 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP4215182A1 (en) | 2015-09-29 | 2023-07-26 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| WO2017165255A1 (en) | 2016-03-25 | 2017-09-28 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| WO2018111738A1 (en) * | 2016-12-15 | 2018-06-21 | Afferent Pharmaceuticals, Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore |
| JP6934945B2 (ja) | 2016-12-20 | 2021-09-15 | アファレント ファーマシューティカルズ インコーポレイテッド | Ｐ２ｘ３アンタゴニストの結晶塩および多形 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| US11440935B2 (en) | 2018-03-15 | 2022-09-13 | Merck Patent Gmbh | 3″,5″-dimethoxybenzoyl-3′-amino-3′-deoxy adenosine-5′-triphosphates and pharmaceutical uses thereof |
| WO2019209607A1 (en) * | 2018-04-23 | 2019-10-31 | Merck Sharp & Dohme Corp. | Novel process for synthesis of a phenoxy diaminopyrimidine compound |
| CA3100099A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| CN112384213A (zh) | 2018-05-15 | 2021-02-19 | 拜耳公司 | 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺 |
| CN118477079A (zh) * | 2018-07-23 | 2024-08-13 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| KR102613204B1 (ko) * | 2018-10-05 | 2023-12-12 | 시오노기 앤드 컴파니, 리미티드 | 만성 해수 치료용 의약 |
| JP7578602B2 (ja) | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| MX2021013338A (es) * | 2019-04-30 | 2022-01-24 | Beijing Tide Pharmaceutical Co Ltd | Método para tratar la tos usando un compuesto de diaminopirimidina. |
| AU2020266699A1 (en) * | 2019-04-30 | 2021-12-16 | Beijing Tide Pharmaceutical Co., Ltd. | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
| CA3155142A1 (en) | 2019-09-19 | 2021-03-25 | Shionogi & Co., Ltd. | Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same |
| WO2021142288A1 (en) | 2020-01-10 | 2021-07-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| CN120019423A (zh) | 2022-10-12 | 2025-05-16 | 软银集团股份有限公司 | 信息处理系统、信息处理装置、控制装置及程序 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1725540T3 (pl) | 2004-03-05 | 2013-02-28 | Hoffmann La Roche | Diaminopirymidyny jako antagoniści p2x3 i p2x2/3 |
| EP1773405A4 (en) | 2004-07-22 | 2011-10-05 | Duska Scient Co | METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES |
| KR101012926B1 (ko) | 2005-09-01 | 2011-02-09 | 에프. 호프만-라 로슈 아게 | Ｐ2ｘ3 및 ｐ2ｘ2/3 조정자로서의 다이아미노피리미딘 |
| JP4820873B2 (ja) * | 2005-09-01 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | アリールオキシジアミノピリミジンの合成方法 |
| JP4850911B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン |
| CN101300235B (zh) | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
| SI2343281T1 (sl) * | 2006-10-04 | 2014-06-30 | F. Hoffmann-La Roche Ag | Postopek za sintezo fenoksi diaminopirimidinskih derivatov |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| US9550763B2 (en) * | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
| MX367657B (es) | 2013-08-23 | 2019-08-30 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
| US9133647B2 (en) * | 2013-10-11 | 2015-09-15 | Nexkey, Inc. | NFC or BLE based contactless lock with charge monitoring of its energy storage |
-
2014
- 2014-08-22 MX MX2016002289A patent/MX367657B/es active IP Right Grant
- 2014-08-22 MY MYPI2016000327A patent/MY195728A/en unknown
- 2014-08-22 UA UAA201601740A patent/UA118851C2/uk unknown
- 2014-08-22 EP EP21159088.0A patent/EP3865134A1/en active Pending
- 2014-08-22 PE PE2016000285A patent/PE20160431A1/es unknown
- 2014-08-22 KR KR1020167007167A patent/KR102196885B1/ko active Active
- 2014-08-22 EP EP14838254.2A patent/EP3035932A4/en not_active Withdrawn
- 2014-08-22 CN CN201480058491.3A patent/CN105682659B/zh active Active
- 2014-08-22 WO PCT/US2014/052389 patent/WO2015027212A1/en not_active Ceased
- 2014-08-22 NZ NZ716977A patent/NZ716977A/en unknown
- 2014-08-22 US US14/466,713 patent/US9284279B2/en active Active
- 2014-08-22 AU AU2014308606A patent/AU2014308606B2/en active Active
- 2014-08-22 SG SG11201601145RA patent/SG11201601145RA/en unknown
- 2014-08-22 CA CA2921395A patent/CA2921395C/en active Active
- 2014-08-22 JP JP2016536497A patent/JP6546592B2/ja active Active
- 2014-08-22 CR CR20160093A patent/CR20160093A/es unknown
- 2014-08-22 RU RU2016105581A patent/RU2650118C2/ru active
-
2016
- 2016-02-02 US US15/013,798 patent/US9724346B2/en active Active
- 2016-02-15 IL IL244131A patent/IL244131B/en active IP Right Grant
- 2016-02-22 CL CL2016000400A patent/CL2016000400A1/es unknown
- 2016-02-22 NI NI201600029A patent/NI201600029A/es unknown
- 2016-02-23 PH PH12016500357A patent/PH12016500357A1/en unknown
-
2017
- 2017-08-01 US US15/665,595 patent/US10206922B2/en active Active
-
2018
- 2018-08-08 CL CL2018002137A patent/CL2018002137A1/es unknown
- 2018-08-08 CL CL2018002138A patent/CL2018002138A1/es unknown
-
2019
- 2019-03-25 JP JP2019055849A patent/JP7210348B2/ja active Active
-
2022
- 2022-10-18 JP JP2022166618A patent/JP7423725B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244131B (en) | p2x3 and p2x 2/3diaminopyrimidine receptor modulators for acute or subacute treatment of chronic cough | |
| IL285375B2 (en) | IL-8-binding antibodies and their uses | |
| HUS2400004I1 (hu) | Diaminopirimidin-P2X3 és P2X2/3 receptor modulátorok felhasználásra köhögés kezelésében | |
| IL257324A (en) | Antibody against glypican-3 and its use | |
| IL259585A (en) | Antibody molecules for april and their uses | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| IL254517B (en) | Antibodies against muc16 and their uses | |
| SG10202103611VA (en) | Anti-lag3 antibodies and uses thereof | |
| IL254955B (en) | Anti-pacap antibodies and their uses | |
| IL245733A0 (en) | aplnr modulators and their uses | |
| IL247847A0 (en) | ror gamma modulator and their use | |
| IL246191A0 (en) | Compounds and methods related to p2x3 and/or p2x2/3 | |
| IL258779B (en) | Modulators of sestrin-gator2 interaction and their uses | |
| GB201503812D0 (en) | Antibody molecules and uses thereof | |
| PT3166636T (pt) | Moduladores de psgl-1 e utilizações dos mesmos | |
| PL3292154T3 (pl) | Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| GB2524448B (en) | Identifying workload and sizing of buffers for the purpose of volume replication | |
| ZA201703649B (en) | Track pads and track assembly | |
| IL252932A0 (en) | Anti-cxcl12 antibody molecules and their uses | |
| GB201520938D0 (en) | Yang-mills existence and mass gap | |
| ZA201606656B (en) | Ror-gamma modulators and uses thereof | |
| GB201506785D0 (en) | Face mask and face seal component |